CalidiBiotherapeutics-Logo@2x.jpg
Calidi Biotherapeutics Reports Second Quarter 2024 Operating and Financial Results
13 août 2024 17h37 HE | Calidi Biotherapeutics, Inc
Launched Nova Cell subsidiary with $2 million investment from Dr. Ronald Rigor to advance Calidi’s Adult Adipose Allogeneic (AAA) stem cell innovative programs Strengthened team with the appointment...
Immatics Final logo (R)_white_background.png
Immatics Announces Second Quarter 2024 Financial Results and Business Update
13 août 2024 07h00 HE | https://immatics.com/
Clinical data from May 2024 on ACTengine® IMA203 targeting PRAME in 30 heavily pre-treated metastatic melanoma patients at RP2D: 55% confirmed objective response rate, median duration of response of...
Transparency Market Research
Bladder Cancer Therapeutics Market is Likely to Reach USD 456.3 million by 2034 at a CAGR of 4.8% | Report Analysis by Transparency Market Research Inc.
09 août 2024 10h18 HE | Transparency Market Research
Wilmington, Delaware, United States, Transparency Market Research, Inc. , Aug. 09, 2024 (GLOBE NEWSWIRE) -- The global bladder cancer therapeutics market(방광암 치료제 시장) stood at US$ 271.4 million in...
22157.jpg
Anti TIGIT Antibodies Clinical Trials Market Outlook to 2028: Insight on 50+ Anti TIGIT Antibodies in Clinical Trials
09 août 2024 05h22 HE | Research and Markets
Dublin, Aug. 09, 2024 (GLOBE NEWSWIRE) -- The "Anti TIGIT Antibodies Clinical Trials & Market Opportunity Outlook 2028" report has been added to ResearchAndMarkets.com's offering. Anti TIGIT...
22157.jpg
Trispecific Antibodies Clinical Trials & Market Outlook Report 2024: Innovative Trispecific Antibody Therapy - A New Frontier in Cancer and Disease Treatment
09 août 2024 04h19 HE | Research and Markets
Dublin, Aug. 09, 2024 (GLOBE NEWSWIRE) -- The "Global Trispecific Antibodies Clinical Trials & Market Outlook 2024" report has been added to ResearchAndMarkets.com's offering.The blueprint in...
22157.jpg
Multispecific Antibodies Market Research, Drug Sales, Price & Clinical Trials Insights 2023-2029: 13 Approved, 900 Multispecific Antibodies in Clinical Trials by Company, Country, Indication, & Phase
09 août 2024 04h16 HE | Research and Markets
Dublin, Aug. 09, 2024 (GLOBE NEWSWIRE) -- The "Global Multispecific Antibodies Market, Drug Sales, Price & Clinical Trials Insight 2029" report has been added to ResearchAndMarkets.com's...
Barinthus Biotherapeutics Pipeline
Barinthus Bio Reports Second Quarter 2024 Update on Corporate Developments and Financial Results
08 août 2024 08h00 HE | Barinthus Biotherapeutics
Barinthus Bio Reports Second Quarter 2024 Update on Corporate Developments and Financial Results
Oncology/Cancer Drugs Market to Reach $335.2 Billion, Globally, by 2033 at 7.2% CAGR: Allied Market Research
01 août 2024 21h30 HE | Allied Analytics LLP
Wilmington, Delaware, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Allied Market Research published a report, titled, "Oncology/Cancer Drugs Market by Drug Class (Chemotherapy, Targeted Therapy, Immunotherapy...
Immatics Final logo (R)_white_background.png
Immatics Appoints Alise Reicin to Board of Directors
31 juil. 2024 07h00 HE | https://immatics.com/
Houston, Texas and Tuebingen, Germany, July 31, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of...
CalidiBiotherapeutics-Logo@2x.jpg
Calidi Biotherapeutics Announces Launch of Nova Cell Subsidiary and $3 Million Aggregate Investment from Dr. Ronald Rigor
29 juil. 2024 09h00 HE | Calidi Biotherapeutics, Inc
SAN DIEGO, July 29, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor...